Results 191 to 200 of about 124,971 (293)

Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival

International Journal of Cancer, Volume 158, Issue 10, Page 2697-2708, 15 May 2026.
What's New? Immune checkpoint inhibitors (ICIs) improve survival in advanced gastroesophageal cancer (GEC), but their benefits may differ by sex. Little is known, however about the impact of sex‐related immune differences on ICI efficacy. In this meta‐analysis, sex‐specific outcomes of ICI therapy were evaluated in advanced GEC, encompassing both ...
Michael Masetti, Fausto Petrelli, Filippo Pietrantonio, Sylvie Lorenzen, Alberto Giovanni Leone   +4 more
wiley   +1 more source

Location characteristics of superficial esophageal squamous cell carcinoma. [PDF]

Sci Rep
Ryu DG, Choi CW, Kim SY, Kim SJ, Park SB, Jang JO, Kim WJ, Son BS.   +7 more
europepmc   +1 more source

What Is Your Diagnosis? Fine‐Needle Aspirate From a Lingual Mass in a Cat

Veterinary Clinical Pathology, EarlyView.
Emma Stacey, Andrii Trokoz, Kimberly Williams, Dorothee Bienzle   +3 more
wiley   +1 more source

Synergistic Effects of DNA‐PKcs Inhibition and Radiotherapy in Esophageal Squamous Cell Carcinoma

The FASEB Journal, Volume 40, Issue 9, 15 May 2026.
Radiotherapy induces double‐strand DNA breaks in esophageal squamous cell carcinoma, triggering DNA‐PKcs phosphorylation and activating the non‐homologous end joining (NHEJ) repair pathway, which contributes to radioresistance. Inhibiting DNA‐PKcs disrupts this repair mechanism, enhancing radiosensitivity by blocking NHEJ, amplifying DNA damage, and ...
Jiekun Qian, Guoliang Liao, Jianting Du, Maojie Pan, Maohui Chen, Long Wu, Xin Yan, Chun Chen, Bin Zheng, Zhang Yang   +9 more
wiley   +1 more source

Peroxiredoxin 4 suppresses ferroptosis in esophageal squamous cell carcinoma by activating the phosphoinositide 3-kinase  signaling pathway. [PDF]

Biomed Rep
Li K, Xu S, Liu H, Fan T, Li Y, Ren R, Xu Y, Li S, Liu Y.   +8 more
europepmc   +1 more source

FGFR Like1 drives esophageal cancer progression via EMT, PI3K/Akt, and notch signalling: insights from clinical data and next‐generation sequencing analysis

FEBS Open Bio, Volume 16, Issue 5, Page 979-999, May 2026.
Clinical analysis reveals significant dysregulation of FGFRL1 in esophageal cancer (EC) patients. RNAi‐coupled next‐generation sequencing (NGS) and in vitro study reveal FGFRL1‐mediated EC progression via EMT, PI3K/Akt, and Notch pathways. Functional assays confirm its role in tumor growth, migration, and invasion.
Aprajita Srivastava, Anoop Saraya, Deepak Gunjan, Rinu Sharma   +3 more
wiley   +1 more source

Metformin Use and Development of Esophageal Squamous Cell Carcinoma.

JAMA Netw Open
Xie SH, Santoni G, Birgisson H, von Euler-Chelpin M, Kauppila JH, Ness-Jensen E, Lagergren J.   +6 more
europepmc   +1 more source

Targeting the ROS-JNK/p38 Axis: Schisandrin A as a Novel Therapeutic Candidate for Esophageal Squamous Cell Carcinoma. [PDF]

J Microbiol Biotechnol
Lee M, Joo SH, Choi YH, Yoon G, Park JW, Shim JH.   +5 more
europepmc   +1 more source

Domain associated with zinc fingers‐containing NF90‐NF45 complex inhibits m6A modification of primary microRNA by suppressing METTL3/14 activity

FEBS Open Bio, Volume 16, Issue 5, Page 921-931, May 2026.
NF90–NF45 functions as a negative regulator of methyltransferase‐like 3/14 (METTL3/14)‐mediated N6‐methyladenosine (m6A) modification on primary microRNAs (pri‐miRNAs). NF90–NF45 binds to anti‐oncogenic pri‐miRNAs and inhibits their m6A modification, thereby suppressing the biogenesis of anti‐oncogenic miRNAs.
Takuma Higuchi, Shunsuke Morioka, Keiko Morisawa, Kazutsugu Matsukawa, Shingo Ashida, Takeshi Suzuki, Shuji Sakamoto   +6 more
wiley   +1 more source

Pseudoachalasia due to Distal Esophageal Squamous Cell Carcinoma in an Elderly Patient: Clinical Insights. [PDF]

Clin Case Rep
Flores CS, Pineda I, Parikh N, Mahmoud HY, Alamin MH.   +4 more
europepmc   +1 more source